AI Becomes the Battleground: Roche, Eli Lilly and Other Multinational Pharma Giants Heavily Bet on AI in 2026

　　【Pharmaceutical Network Industry DynamicsOn May 7, Roche announced the acquisition of PathAI, an American AI company, to deepen their partnership that began in 2021. The transaction is expected to be completed in the second half of the year. According to the agreement, Roche will pay $750 million and may additionally pay up to $300 million in milestone payments.
 

Data shows that PathAI is a U.S.-based company focusing on digital pathology and providing artificial intelligence technology for pathology laboratories and the biopharmaceutical industry. Its image management system and AI analysis platform can transform cumbersome manual pathology workflows into automated, AI-driven processes. This acquisition will strengthen Roche's position in the digital pathology field and drive the industry’s transition to fully automated AI processes. Digital pathology technology can streamline diagnostic procedures, helping patients receive test results more quickly.
 

The industry believes that Roche's agreement to acquire PathAI highlights its accelerating efforts in the "AI + healthcare" sector, particularly in the niche fields of "AI + diagnostics/digital pathology/precision oncology." In fact, since 2026, Roche's activities in the AI + healthcare domain have significantly accelerated, advancing along two main tracks: "AI-powered R&D" and "AI-integrated diagnostics," deeply embedding artificial intelligence into the entire value chain from drug discovery to commercialized patient services.
 

It is reported that on March 16, Roche announced the expansion of its global artificial intelligence infrastructure, deploying a large-scale AI factory that adopts a full suite of the latest NVIDIA accelerated computing and AI technologies.
 

The AI factory combines world-class computing power with Roche's scientific expertise, embedding AI throughout the entire value chain — from discovery to development, manufacturing, and commercialization. In addition, the AI factory will support the use of "digital twins" in Roche’s manufacturing to improve processes and factory design, and facilitate the development of digital pathology software to derive insights from medical images, as well as digital health tools based on "secure and reliable medical-grade conversational AI."
 

Roche's two core initiatives in 2026 clearly demonstrate that it has regarded AI as a key driver to run through the entire value chain and reshape its core business. Notably, besides Roche, many leading pharmaceutical companies are also accelerating the transformation of artificial intelligence from an "auxiliary tool" to "core infrastructure" that reconfigures the entire process of R&D, production, and commercialization.
 

Sanofi recently announced that it will invest $294 million (approximately RMB 2 billion) to expand its Global Artificial Intelligence Center of Excellence located in Toronto. It is reported that the Toronto AI Center of Excellence is a key carrier for Sanofi to leverage artificial intelligence and accelerate the realization of its core mission to "halve the time from discovery to implementation of innovative therapies." At the same time, it represents a further deepening of Sanofi's end-to-end AI layout.
 

Six months ago, it also partnered with Canadian software company BenchSci to leverage the latter's AI co-pilot tool ASCEND. By integrating publicly available scientific research information with proprietary internal corporate data, they built a knowledge graph to help researchers gain deeper insights into disease biology mechanisms, thereby enhancing drug development efficiency from the ground up.
 

Lilly has also completed two AI collaborations within the past three months. On April 28, Lilly reached a multi-project strategic partnership with AI biotech company Profluent to jointly develop AI-designed site-specific recombinase gene-editing therapies, with a total deal value of up to $2.25 billion.
 

On March 29, Eli Lilly and Insilico Medicine reached a drug discovery and AI pipeline licensing collaboration, including the licensing of a novel oral drug pipeline and a drug development partnership involving multiple selected targets. According to the agreement, Insilico Medicine is eligible to receive an upfront payment of $115 million and additional payments upon achieving development, regulatory, and commercialization milestones, with the total value of the deal reaching approximately $2.75 billion.
 

　　……
 

Since 2026, the intensive actions of large multinational pharmaceutical companies in the AI field have shown that the integration of AI and pharmaceuticals has entered the "large-scale implementation" and "deep-water zone breakthrough" stage. In the future, companies that can first deeply embed AI into the entire chain of R&D, clinical trials, and production are expected to occupy a core position in global pharmaceutical innovation.
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.